-
PROVIDERS
Watch now
Are you getting the full picture? A webinar series on the power of comprehensive intelligent diagnostics
-
LIFE SCIENCES
ENROLL NOW
Tempus’ Patient-Derived Organoid ScreensEvaluate the efficacy of your preclinical compounds using fixed organoid panels designed for diverse therapeutic applications.Space is limited — enroll by June 30, 2025, to secure your spot.
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
06/26/2023
Roswell Park Comprehensive Cancer Center
Researchers from Tempus partnered with the Roswell Park Comprehensive Cancer Center to study aberrations in patients with metastatic non-small cell lung cancer.
FGFR fusions represent a potential mechanism of resistance to EGFR inhibitors. This study characterizes the prevalence of these alterations and the landscape of co-mutations that may be of high interest to drug developers targeting FGFR fusions.
This study was presented at the Targeted Therapies of Lung Cancer Meeting in February 2023.
-
06/12/2025AI & ML in action: Demonstrating real-world impact in trial design & patient care
Discover how the Tempus platform leverages AI and ML to inform standard of care practices through health equity guidelines and drive insights that help refine clinical trial design. Engage with live demonstrations showcasing how our tools identify patients by modifying inclusion/exclusion criteria and leveraging patient queries. Explore how our tools integrate NCCN guidelines and empower life science teams to access current, actionable patient-journey insights. Learn how these real-world applications can drive progress in your clinical development initiatives.
Watch replay
Secure your recording now. -
06/09/2025Bridging the translational gap: The role of organoids in oncology R&D
This white paper explores the evolving role of organoids in oncology R&D, highlighting their potential as predictive preclinical models and their ability to reduce translational risk. Download for a comprehensive overview of the scientific landscape, key adoption barriers, emerging innovations, and how pharma companies leverage organoids to accelerate precision medicine.
Read more -
03/25/2025The RNA advantage: A multimodal approach to accelerating oncology R&D
Discover how transcriptomic data and multi-omics data integrated with AI is helping revolutionize oncology drug development and patient care and fueling precision medicine 2.0. Learn about RNA sequencing’s role in companion diagnostics and Tempus Loop’s capabilities to support target identification and validation.
Watch replay
Secure your recording now.